Literature DB >> 9743405

Formulation-dependent brain and lung distribution kinetics of propofol in rats.

S Dutta1, W F Ebling.   

Abstract

BACKGROUND: Propofol when administered by brief infusion in a lipid-free formulation has a slower onset, prolonged offset and greater potency compared with an emulsion formulation. To understand these findings the authors examined propofol brain and lung distribution kinetics in rats.
METHODS: Rats were infused with equieffective doses of propofol in emulsion (n = 21) or lipid-free formulation (n = 21). Animals were sacrificed at various times to harvest brain and lung. Arterial blood was sampled repeatedly from each animal until sacrifice. Deconvolution and moment analysis were used to calculate the half-life for propofol brain turnover (BT) and brain:plasma partition coefficient (Kp). Lung concentration-time profiles were compared for the two formulations.
RESULTS: Peak propofol plasma concentrations for the lipid-free formulation were 50% of that observed for emulsion formulation, whereas peak lung concentrations for lipid-free formulation were 300-fold higher than emulsion formulation. Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively. BT were 2.4 and 2.5 min for emulsion and lipid-free formulations, respectively.
CONCLUSIONS: Significant pulmonary sequestration and slow release of propofol into arterial circulation when administered in lipid-free vehicle accounts for the lower peak arterial concentration and sluggish arterial kinetics relative to that observed with the emulsion formulation. Higher Kp for the lipid-free formulation could explain the higher potency associated with this formulation. BT were independent of formulation and correlated with values reported for effect-site equilibration half-time consistent with a distribution mechanism for pharmacologic hysteresis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743405     DOI: 10.1097/00000542-199809000-00018

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain.

Authors:  Haruhiko Hiraoka; Koujirou Yamamoto; Soutarou Miyoshi; Toshihiro Morita; Katsunori Nakamura; Yuuji Kadoi; Fumio Kunimoto; Ryuya Horiuchi
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

2.  Cerebrospinal fluid and plasma propofol concentration during total intravenous anaesthesia of patients undergoing elective intracranial tumor removal.

Authors:  Wei Luo; Yu-Hong Li; Jian-Jun Yang; Jie Tian; Jian-Guo Xu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

3.  A novel, lipid-free nanodispersion formulation of propofol and its characterization.

Authors:  Hongming Chen; Zhong Zhang; Orn Almarsson; Jean-Francois Marier; Dina Berkovitz; Colin R Gardner
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate.

Authors:  Ervin Pejo; Joseph F Cotten; Elizabeth W Kelly; Ri Le Ge; Gregory D Cuny; Joydev K Laha; Jifeng Liu; Xiang Jie Lin; Douglas E Raines
Journal:  Anesth Analg       Date:  2011-09-29       Impact factor: 5.108

5.  The Suitability of Propofol Compared with Urethane for Anesthesia during Urodynamic Studies in Rats.

Authors:  Adam A Moheban; Huiyi H Chang; Leif A Havton
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-01       Impact factor: 1.232

6.  The future of anaesthetic pharmacology.

Authors:  Y K Batra
Journal:  Indian J Anaesth       Date:  2009-10

7.  Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers.

Authors:  Krystyna M Wozniak; James J Vornov; Bipin M Mistry; Ying Wu; Rana Rais; Barbara S Slusher
Journal:  J Transl Med       Date:  2015-05-29       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.